Petros Pharmaceuticals, Inc.
NASDAQ: PTPI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Joshua N. Silverman
- Employees
- 18
- Headquarters
- New York City, United States
- IPO year
- 2020
- Market cap
- $187.0K
- Website
- https://www.petrospharma.com
Loading PTPI…
Loading profile data…Frequently asked questions about PTPI
What does Petros Pharmaceuticals, Inc. (PTPI) do?
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation...
Where does PTPI trade?
Petros Pharmaceuticals, Inc. (PTPI) trades on the NASDAQ Capital Market.
What sector is PTPI in?
Petros Pharmaceuticals, Inc. (PTPI) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Petros Pharmaceuticals, Inc.?
Joshua N. Silverman is the chief executive officer of Petros Pharmaceuticals, Inc. (PTPI).
Where is Petros Pharmaceuticals, Inc. headquartered?
Petros Pharmaceuticals, Inc. is headquartered in United States.
Does PTPI pay a dividend?
Petros Pharmaceuticals, Inc. (PTPI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PTPI go public?
Petros Pharmaceuticals, Inc. (PTPI) completed its initial public offering in 2020.